Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease [2]

Movement Disorders

Volumn 21, Issue 5, 2006, Pages 727-728

  Garcia Ruiz, Pedro J ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIPARKINSON AGENT; APOMORPHINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; ROPINIROLE;

AGED; CASE REPORT; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DYSKINESIA; FEMALE; GAIT DISORDER; HUMAN; INSOMNIA; LETTER; MOTOR DYSFUNCTION; NIGHT; NOCTURIA; PARKINSON DISEASE; PRIORITY JOURNAL; REFLEX DISORDER; SLEEP DISORDER; SLEEP PATTERN; TREATMENT DURATION; TREATMENT OUTCOME; WAKEFULNESS;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; PARKINSON DISEASE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33646911044     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20852     Document Type: Letter

References (15)

1. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988; 11:512-519.
2. Askenazy JJ. Sleep disturbances in Parkinsonism. J Neural Transm 2003;110:125-150.
3. Stocchi F, Vacca L, Valente M, Ruggieri S. Sleep disorders in Parkinson's disease. Adv Neurol 2001;86:289-293.
4. Diederich N, Comella C. Sleep disturbances in Parkinson's disease. In: Chokroverty S, Hening WA, Walters A, editors. Sleep and movement disorders. Philadelphia: Butterworth, Heinemann; 2003. p. 478-488.
5. van Hilten B, Hoff JI, Middelkoop HA, et al. Sleep disruption in Parkinson's disease: assessment by continuous activity monitoring. Arch Neurol 1994;51:922-928.
6. Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology 2005;64:1450-1451.
7. Pollak CP, Tryon WW, Nagaraja H, Dzwonczyk R. How accurately does wrist actigraphy identify the states of sleep and wakefulness? Sleep 2001;24:957-965.
8. Tryon WW. Issues of validity in actigraphic sleep assessment. Sleep 2004;27:158-165.
9. Jean-Louis G, von Gizycki H, Zizi F, et al. Determination of sleep and wakefulness with the actigraph data analysis software (ADAS). Sleep 1996;19:739-743.
10. Jean-Louis G, von Gizycki H, Zizi F, Spielman A, Hauri P, Taub H. The actigraph data analysis software: I, a novel approach to scoring and interpreting sleep-wake activity. Percept Mot Skills 1997;85:207-216.
11. Reuter I, Ellis CM, Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999;100:163-167.
12. Priano L, Albani G, Brioschi A, et al. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. Neurol Sci 2003;24:207-208.
13. Bonuccelli U, Piccini P, Del Dotto P, Rossi G, Corsini GU, Muratorio A. Naloxone partly counteracts apomorphine side effects. Clin Neuropharmacol 1991;14:442-449.
14. Montastruc JL, Rascol O, Montastruc P. Naloxone or haloperidol but not yohimbine reverse apornorphine-induced respiratory depression. Clin Neuropharmacol 1992;15:404-407.
15. Hu WM, Kang YM, Qiao JT. Involvement of endogenous opioids and ATP-sensitive potassium channels in the mediation of apomorphine-induced antinociception at the spinal level: a study using EMG planimetry of flexor reflex in rats. Brain Res Bull 1999;48:315-318.